Bionime Résultats passés
Passé contrôle des critères 0/6
Bionime's earnings have been declining at an average annual rate of -26.1%, while the Medical Equipment industry saw earnings growing at 11.2% annually. Revenues have been declining at an average rate of 1.4% per year.
Informations clés
-26.1%
Taux de croissance des bénéfices
-27.2%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 11.5% |
| Taux de croissance des recettes | -1.4% |
| Rendement des fonds propres | -2.1% |
| Marge nette | -2.1% |
| Prochaine mise à jour des résultats | 06 Nov 2024 |
Mises à jour récentes des performances passées
Recent updates
Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2
Jul 22
Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year
Jul 01These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong
Apr 29Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?
Mar 23Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?
Mar 05Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?
Feb 15
Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet
Feb 01How Has Bionime (TPE:4737) Allocated Its Capital?
Jan 19A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE
Jan 06A Look At The Fair Value Of Bionime Corporation (TPE:4737)
Dec 22Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend
Dec 09Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment
Nov 24Ventilation des recettes et des dépenses
Comment Bionime gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 1,858 | -40 | 559 | 303 |
| 31 Mar 24 | 1,809 | 7 | 507 | 247 |
| 31 Dec 23 | 1,756 | 6 | 487 | 242 |
| 30 Sep 23 | 1,863 | 22 | 538 | 218 |
| 30 Jun 23 | 2,002 | 43 | 594 | 211 |
| 31 Mar 23 | 2,150 | 72 | 649 | 207 |
| 31 Dec 22 | 2,211 | 91 | 671 | 202 |
| 30 Sep 22 | 2,091 | 95 | 588 | 194 |
| 30 Jun 22 | 2,023 | 115 | 567 | 189 |
| 31 Mar 22 | 1,862 | 89 | 525 | 185 |
| 31 Dec 21 | 1,850 | 87 | 520 | 188 |
| 30 Sep 21 | 1,879 | 101 | 546 | 188 |
| 30 Jun 21 | 1,832 | 111 | 534 | 209 |
| 31 Mar 21 | 1,779 | 83 | 532 | 231 |
| 31 Dec 20 | 1,669 | 62 | 480 | 248 |
| 30 Sep 20 | 1,913 | 73 | 531 | 261 |
| 30 Jun 20 | 1,951 | 38 | 532 | 266 |
| 31 Mar 20 | 2,162 | 91 | 558 | 276 |
| 31 Dec 19 | 2,173 | 106 | 537 | 255 |
| 30 Sep 19 | 2,043 | 112 | 468 | 254 |
| 30 Jun 19 | 2,113 | 132 | 473 | 233 |
| 31 Mar 19 | 1,986 | 121 | 452 | 205 |
| 31 Dec 18 | 2,007 | 128 | 475 | 201 |
| 30 Sep 18 | 1,962 | 114 | 475 | 190 |
| 30 Jun 18 | 1,842 | 135 | 438 | 171 |
| 31 Mar 18 | 1,821 | 137 | 396 | 165 |
| 31 Dec 17 | 1,820 | 150 | 387 | 160 |
| 30 Sep 17 | 1,771 | 174 | 369 | 140 |
| 30 Jun 17 | 1,780 | 181 | 365 | 146 |
| 31 Mar 17 | 1,791 | 192 | 378 | 145 |
| 31 Dec 16 | 1,740 | 179 | 372 | 140 |
| 30 Sep 16 | 1,654 | 143 | 375 | 137 |
| 30 Jun 16 | 1,637 | 119 | 386 | 133 |
| 31 Mar 16 | 1,571 | 91 | 389 | 124 |
| 31 Dec 15 | 1,610 | 99 | 394 | 118 |
| 30 Sep 15 | 1,634 | 101 | 386 | 109 |
| 30 Jun 15 | 1,591 | 82 | 353 | 97 |
| 31 Mar 15 | 1,571 | 72 | 351 | 93 |
| 31 Dec 14 | 1,525 | 54 | 353 | 92 |
| 30 Sep 14 | 1,446 | 22 | 335 | 103 |
| 30 Jun 14 | 1,459 | 43 | 353 | 106 |
| 31 Mar 14 | 1,536 | 72 | 376 | 102 |
| 31 Dec 13 | 1,561 | 90 | 382 | 101 |
Des revenus de qualité: 4737 is currently unprofitable.
Augmentation de la marge bénéficiaire: 4737 is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 4737 is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.
Accélération de la croissance: Unable to compare 4737's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: 4737 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.5%).
Rendement des fonds propres
ROE élevé: 4737 has a negative Return on Equity (-2.09%), as it is currently unprofitable.